Back to top

Press Releases

Zacks Equity Research

The Zacks Analyst Blog Highlights: BioShares Biotechnology Clinical Trials Fund, Guggenheim S&P SmallCap 600 Pure Value ETF, PowerShares S&P SmallCap Materials Fund, Health Insurance Innovations and Airgain

BBC RZV PSCM HIIQ AIRG

Trades from $3

For Immediate Release

Chicago, IL – November 17, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include BioShares Biotechnology Clinical Trials Fund (NASDAQ: (BBC - Free Report) - Free Report ) , Guggenheim S&P SmallCap 600 Pure Value ETF (NYSEARCA: (RZV - Free Report) - Free Report ) , PowerShares S&P SmallCap Materials Fund (NASDAQ:(PSCM - Free Report) - Free Report ) , Health Insurance Innovations Inc. (NASDAQ:(HIIQ - Free Report) -Free Report ) and Airgain Inc. (NASDAQ:(AIRG - Free Report) -Free Report ) .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday’s Analyst Blog:

Small-Caps Win on Trump Rally: 5 Top ETFs and Stocks

Market sentiments turned extremely bullish after the election with most indices logging in the best week in five years. Though the Dow Jones rose 3.2% since November 8, the Russell 2000 is outperforming with 9% gains.


The returns were mainly driven by Trump’s massive stimulus policies that should benefit small caps more as these are closely tied to the U.S. economy and generate most of their revenues from the domestic market. He seeks to double the pace of economic growth from the current 2%, create 25 million jobs over 10 years, and make the U.S. economy the strongest in the world.

Additionally, comparatively higher weightings to healthcare and financials – the two sectors that Trump loves – have given an edge to the Russell 2000 Index. Trump seeks fewer regulations in these sectors (read: The Trump Effect: 8 Must-See ETF Charts).

Small cap stocks generally outperform when the American economy is leading the way. Since these companies are small, they are poised to grow more than their already tapped out large-cap counterparts. Further, Trump’s proposed renegotiation or termination of the North American Free Trade Agreement and building a Mexico wall would favor small cap stocks in case it results in a trade war or a tariff increase as expected.

Given this, there have been winners in many corners of the small cap space. Below we have presented five ETFs & stocks that have easily crushed the Russell 2000 index and are likely to continue their strong performance going forward:

Best ETFs

All these funds have a favorable Zacks Rank of 1 (Strong Buy), 2 (Buy) or 3 (Hold), suggesting more room for upside.

BioShares Biotechnology Clinical Trials Fund ( NASDAQ: (BBC - Free Report) - Free Report )

This ETF provides exposure to biotechnology companies that have a primary product in Phase I, II, or III of FDA trials by tracking the LifeSci Biotechnology Clinical Trials Index (read: 5 Reasons to Buy 5 Low P/E Biotech ETFs).

Zacks ETF Rank: #3
AUM: $22.1 million

Expense Ratio: 0.85%
5-Day Return: 21.1%

Guggenheim S&P SmallCap 600 Pure Value ETF ( NYSEARCA: (RZV - Free Report) - Free Report )

This fund provides pure exposure to the small cap value segment of the U.S. equity market by tracking the S&P SmallCap 600 Pure Value Index.

Zacks ETF Rank: #3
AUM: $218.8 million
Expense Ratio: 0.35%
5-Day Return: 14.1%

PowerShares S&P SmallCap Materials Fund ( NASDAQ:(PSCM - Free Report) - Free Report )

This ETF targets the material sector and tracks the S&P SmallCap 600 Capped Materials Index (read: Sector ETFs Hitting 52-Week High on Trump's Victory ).

Zacks ETF Rank: #2
AUM: $26.9 million
Expense Ratio: 0.29%
5-Day Return: 13.5%

Best Stocks

We have used our Zacks stock screener to find out the best performing stocks in the small cap space and then narrowed down the list of the stocks having a Zacks Rank #1 or 2 and a Growth Style Score of ‘B’ or better.

The Growth Style Score analyzes the growth prospects of a company following a thorough analysis of the income statement, balance sheet and cash flow statement that evaluate its financial health and the sustainability of its growth trajectory. The results show that stocks with a Growth Style Score of A or B when combined with a Zacks Rank #1 or 2 offer the best upside potential.

Health Insurance Innovations Inc. ( NASDAQ:(HIIQ - Free Report) -Free Report )

This Florida-based company operates as a developer and administrator of cloud-based individual health and family insurance plans, and supplemental products in the United States (read: Trump Triumphs: Stocks & ETFs to Rock or Shock ).

Zacks Rank: #1
Growth Style Score: A
Market Cap: $150.2 million
5-Day Return: 74.6%

Airgain Inc. ( NASDAQ:(AIRG - Free Report) -Free Report )

This California-based company is engaged in designing, developing, and engineering antenna products for original equipment and design manufacturers, chipset vendors, and service providers worldwide.

Zacks Rank: #2
Growth Style Score: B
Market Cap: $147.4 million
5-Day Return: 60.6%

Bottom Line

These ETFs and stocks could be lucrative picks going forward, as small caps are considered the barometer of the domestic economy and are poised for accelerated growth under the Trump presidency.

Want key ETF info delivered straight to your inbox?

Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on BBC - FREE

Get the full Report on RZV - FREE

Get the full Report on PSCM - FREE

Get the full Report on HIIQ - FREE

Get the full Report on AIRG - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.